Category: Clinical Trials & News
Apple’s Restrictions on Peptide App Calculators: What Canadian Researchers Should Know
← Back to Research & Articles Laboratory Research & Educational Notice: This article explains Apple’s rules for drug dosage calculator apps and discusses online peptide research tools available to Canadian researchers. Standard Labs educational resources are intended for laboratory research, not medical dosing, diagnosis, or treatment. Are peptide calculator apps disappearing from the Apple App […]
Read more →
Oral Triple-G (LY4086940): Eli Lilly’s Next-Generation Oral Triple Agonist
Back to Research & Articles Laboratory Compliance Notice: LY4086940 (Oral Triple-G) is an investigational compound being evaluated in clinical research. It is not an approved treatment for obesity, diabetes, or other medical conditions. Its clinical safety, effectiveness, and long-term outcomes remain under investigation. Eli Lilly is advancing a new investigational oral triple-receptor agonist known as […]
Read more →
Oral Semaglutide Delivery: What Orexo’s New AmorphOX Results Could Mean for Peptide Pills
Orexo’s early AmorphOX results explore another route to oral semaglutide. Learn what absorption means, why formulation matters and what comes next.
Read more →
DTI-117: A New Peptide Approach to More Predictable Bowel Care
DTI-117 research explores rapid, on-demand bowel emptying. Understand the new animal findings, potential benefits and planned first human study.
Read more →
MOTS-c and Eye Health: New Research Explores Protection Against Diabetic Retinopathy
New MOTS-c research explores retinal blood vessel protection in cells and mice. Discover the findings, potential benefits and next steps for eye health.
Read more →
Eloralintide Phase 2: What Selective Amylin Could Add to Weight Management
Eloralintide Eloralintide standalone phase 2 explained: study results, benefits, key insights and next steps in clear language, with links to the…
Read more →
EloraTZP Trial Results: Why Combining Amylin and Tirzepatide Matters
EloraTZP EloraTZP phase 2b explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →
Oral VK2735 VENTURE Results: A Peptide Tablet With Strong Early Weight Loss
VK2735 VENTURE-Oral explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →
Retatrutide TRIUMPH-2: Weight Loss and Blood-Sugar Results Explained
Retatrutide TRIUMPH-2 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →
VK2735 Maintenance Trial: Could Less Frequent Treatment Preserve Weight Loss?
VK2735 VK2735 maintenance study explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →
Retatrutide TRIUMPH-3: Promising Weight Results in People With Heart Disease
Retatrutide TRIUMPH-3 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →
Petrelintide ZUPREME-1: An Amylin Approach With a Promising Weight Signal
Petrelintide ZUPREME-1 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →
Retatrutide TRIUMPH-1: What the 28.3% Weight-Loss Result Really Means
Retatrutide TRIUMPH-1 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →
Pemvidutide IMPACT: What Improving Liver Markers Could Mean for MASH
Pemvidutide IMPACT 48-week update explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.
Read more →